Danaher deal for GE biopharma unit gets US FTC approval after company agrees to divest assets
MLex Summary: Danaher agreed to divest assets to settle US Federal Trade Commission charges that its deal for General Electric's biopharmaceutical business would violate antitrust law. The FTC said the deal...To view the full article, register now.
Already a subscriber? Click here to view full article